



NIH PUBLIC ACCESS

## Author Manuscript

*Menopause*. Author manuscript; available in PMC 2010 April 19.

Published in final edited form as:

*Menopause*. 2008 ; 15(5): 940–944. doi:10.1097/gme.0b013e31816429e5.

## Mother's Menopausal Age is Associated with her Daughter's Early Follicular Phase Urinary, Follicle Stimulating Hormone Level

Anne Z. Steiner, MD, MPH<sup>a</sup>, Donna D. Baird, PhD<sup>b</sup>, and James S. Kesner, PhD<sup>c</sup><sup>a</sup> Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Cincinnati, OH<sup>b</sup> Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Cincinnati, OH<sup>c</sup> Biomonitoring and Health Assessment Branch, Division of Applied Research and Technology, National Institutes of Occupational Safety and Health, Cincinnati, OH

### Abstract

**OBJECTIVE**—Early follicular phase follicle stimulating hormone (FSH), a marker of ovarian reserve, has been used to predict time to menopause. A mother's age at menopause is related to daughter's age at menopause, possibly due to genetic factors. This study sought to determine the relationship between maternal age at menopause and early follicular phase FSH of premenopausal daughters.

**DESIGN**—The Uterine Fibroid Study enrolled women randomly selected from a prepaid health plan, collected questionnaire data, and obtained early follicular phase urine samples on a subset of participants. For this secondary analysis, premenopausal women between the ages of 35 and 46 years, who provided a urine sample on cycle day 2,3,4, or 5 and their mother's age at natural menopause (N=182) were selected from the original cohort. Initially bivariate analysis and subsequently regression modeling was conducted to assess the independent relationship between maternal age at menopause and urinary creatinine-corrected FSH.

**RESULTS**—Unadjusted analyses and those adjusting for age (mean, 40.5 ±3.2 years), smoking status (16 % current smokers), and body mass index (mean, 26.8 ±6.9 kg/m<sup>2</sup>) showed a significant association between maternal age at menopause and daughter's urinary FSH level (p<0.04). Women whose mothers experienced earlier menopause had higher urinary FSH levels.

**CONCLUSIONS**—The significantly increased FSH values among women whose mothers experienced early menopause is consistent with previously reported associations between mother's and daughter's age of menopause. FSH, a marker of reserve of the ovary, is influenced by both genetic and environmental factors. Future epidemiologic studies on FSH should collect information on maternal age at menopause.

### Keywords

Follicle stimulating hormone; menopause; maternal age at menopause

## INTRODUCTION

Reproductive aging of women is the natural progression through stages of puberty, fertility, subfertility, the menopause transition and finally menopause.<sup>1</sup> Women progress through these reproductive stages due to a decline in both the quantity and quality of ovarian oocytes and follicles. In the aging ovary, fewer follicles results in reduced follicular production of the hormone inhibin B, leading to diminished suppression of the anterior pituitary, increased follicle stimulating hormone (FSH) production, and higher serum FSH levels during the early follicular phase of the menstrual cycle. Accordingly, early follicular phase serum FSH levels rise as the number of remaining oocytes declines.

Based on the hormonal changes observed with ovarian aging, serum FSH levels have been used as an indirect marker of reproductive potential. FSH levels are predictive of fecundity with fertility treatment.<sup>2</sup> Levels appear to rise as a woman goes through the menopausal transition from menstrual regularity to irregularity to amenorrhea.<sup>3</sup> In addition, FSH values appear to correlate with time to menopause in women between the ages of 40 and 49, and extreme FSH levels (>20 IU/L) are predictive of menopause (positive predictive value: 73%).<sup>5</sup> Urinary FSH is highly correlated with serum values ( $r=0.75-0.88$ ) and acts similarly as a marker of ovarian aging.<sup>6,7</sup>

Women may vary in age at menopause due to differences in the size of the oocyte pool at birth or to differences in the rate of oocyte loss.<sup>8</sup> Previous studies have shown that both genetic and environmental factors determine the age at which women will enter menopause.<sup>9,10</sup> Maternal menopausal age appears to be a strong predictor of age at menopause.<sup>11-13</sup> The mechanism by which a mother's age at menopause determines the daughter's age at menopause is not known.

Assuming women destined to undergo early menopause will have a smaller oocyte pool, early follicular phase FSH should be higher in this group of women compared to women destined to go through menopause later. Based on this assumption, FSH values should be higher in women whose mothers had an early menopausal age compared to women with mothers with a later menopausal age. This study sought to test this hypothesis by determining the relationship between maternal age at menopause and early follicular phase FSH among late reproductive age women.

## METHODS

This study is a secondary analysis of data from the National Institute of Environmental Health Sciences Uterine Fibroids Study, which was designed to 1) measure prevalence of fibroids by screening a representative group of women and 2) identify risk factors for the condition. A detailed description of the study design has been published previously.<sup>14</sup> In summary, 35-49 year old women were selected randomly from computerized membership records of a prepaid health plan in Washington, DC. Health plan members were eligible if they could be contacted by telephone, their records confirmed, and they spoke English.

Demographic information, reproductive status, medical history, and social history were obtained from participants (N= 1430) using a combination of a self-administered questionnaire and telephone interview. The take-home, self-administered questionnaire included questions about the cause of the mother's menopause (natural or surgical) and age it occurred, allowing respondents to possibly query their mothers. Of the 1237 women that completed the questionnaire 62% provided information about their mother's type and age of menopause.

The first 638 of the 1243 premenopausal participants were asked to collect first morning urine samples on the second and third days of their menstrual cycles. The samples were initially stored in the subject's refrigerator and then shipped within a day via overnight courier in a cold-storage pack to the study management site in North Carolina where equal aliquots from each day were pooled. The premenopausal subjects who did not collect menstrually-timed urine were asked to bring a first morning urine specimen, collected the day of their study clinic visit. Those participants that presented to the clinic without urine were asked to provide a spot urine sample, and their menstrual cycle day was recorded. Seven percent glycerol was added to all samples and the samples stored at  $-80^{\circ}\text{C}$  to prevent loss of hormone activity.<sup>15</sup> In all, 927 women provided urine, but many of these were not early follicular phase specimens. Serum FSH values have been shown to be consistent between menstrual cycle days 2–5,<sup>16–17</sup> so we limited analysis to specimens from those days. There were a total of 467 women with urine samples from menstrual days 2–5; 383 of them were 46 years of age or less. Of the 383 women, 344 (90%) provided 2day pooled first-morning urine samples, 30 (8%) provided single first morning urine samples, and 8 (2%) provided single spot urine samples.

Urinary FSH was assayed in duplicate using a modified commercial non-competitive, two-site time-resolved immunofluorometric assay.<sup>18</sup> Creatinine was measured spectrophotometrically.<sup>19</sup> Endocrine values were divided by creatinine concentrations to adjust for urine dilution.<sup>20</sup> Within-and between-assay percent coefficients of variation were 3.1% and 1.1% for FSH and 2.2% and 4.2% for creatinine.

We limited analysis to participants who were age 46 or younger for two reasons. First, very few women in our sample had experienced natural menopause by age 46, so selection of premenopausal women would not bias our analysis. Second, previous studies have shown that FSH and age are very highly associated for older women.<sup>5,21</sup> By restricting our analysis, any relationship between mother's age at menopause and FSH would not be as obscured by the strong association between FSH and age.

Mother's age at menopause was grouped into three categories: less than 46 years of age, 46 to 49 years, and 50 years or older. If the daughter reported that her mother had surgical menopause before age 50, her age at menopause could not be categorized, but if the daughter reported her mother had surgical menopause and surgery occurred after age 50 (N=17), mother's age at menopause was grouped in the 50 and over category. Of the 383 women with FSH data, 239 (62%) provided information about their mother's type and age of menopause. The 57 subjects (24%), who reported that their mother underwent surgical menopause before age 50, were excluded, leaving 182 for analysis of the relationship between maternal age at menopause and daughter's urinary FSH. *Data Analysis*

Analysis of variance and linear regression were used to determine the unadjusted relationship between FSH and each of the following variables: maternal age at menopause, age, race, education, body mass index, parity by age 35, and smoking status. Subsequently a model was created to assess the independent relationship between maternal age at menopause and urinary FSH (after log transformation) adjusting for potential confounders. Independent variables were considered to be confounders if they changed the measure of association between maternal age at menopause and urinary FSH by more than 10%. Categorical variables (smoking status, race, and education) were modeled using indicator variables. Parity by age 35 was coded as a ranked categorical variable. Age, BMI, and cycle day were modeled as continuous variables. The final model included age, current smoking status (yes/no), and BMI as covariates. Urinary FSH values were estimated for each independent variable (categorized for presentation purposes) using analysis of covariance with covariates set to the mean. Significance of the relationship between each independent

variable and urinary FSH was determined using a t-test for continuous or dichotomous variables, F-test for categorical variables, and a test of trend t-test for ranked variables. The robustness of the maternal age at menopause effect was evaluated by substituting the mean for each category (mean for those with natural menopause, 52.7 years, used for the maternal age at menopause category of 50+).

## RESULTS

We compared daughters with data on mother's age at menopause to those without data. Compared to daughters without, those with data on mother's age at menopause were lighter weight (mean BMI=26.8 ±6.9 kg/m<sup>2</sup> versus 29.1 ±8.1, p=0.003), better educated (p=0.01), less likely to smoke (16% versus 24%, p=0.05), more likely to be white (45% versus 32%, p=0.05) but similar in age (40.9 ±3.0 years versus 40.5 ± 3.2, p=0.2). Average FSH of the daughters for whom we could not categorize mother's age at menopause (N=201) was similar to that of the daughters for whom we could categorize mother's age at menopause (N=182) (11.2 versus 11.1 mIU/mg creatinine, respectively, p=0.9).

Early follicular phase FSH values ranged from 0.58–69.3 mIU/mg creatinine (mean 11.1., median 9.3). Unadjusted analyses showed that of the covariates, only smoking status was a statistically significant predictor of early follicular phase urinary FSH. Current smokers had higher early follicular phase urinary FSH values than current non-smokers (14.5 ±12.5mIU/mg creatinine versus 10.5 ±6.8, p=0.03). BMI was next most important but not statistically significant (p=0.06). As BMI increased, FSH values decreased. Values did not differ by age, day of collection (day 2,3,4, or 5) (P=0.7), race, education level, or parity by age 35.

Table 1 shows the relationship between maternal age at menopause and participant urinary FSH level. Early maternal menopause was significantly associated with higher urinary FSH levels in their daughters (P< 0.04 for both unadjusted and age-adjusted analyses). The relationship was somewhat stronger with full covariate adjustment (P = 0.01). Substituting the categorical mean maternal age at menopause for each individual maternal age at menopause in the model confirmed the significance of the relationship (P=0.01).

In the fully-adjusted model, smoking and BMI were the only covariates significantly associated with FSH levels. Current smokers had significantly higher urinary FSH values compared to current non-smokers (estimated urinary FSH: 12.0 versus 8.6 mIU/mg creatinine respectively, P < 0.02), and obese women had lower urinary FSH values compared to women in the three lower categories of BMI (estimated urinary FSH: 7.1 versus 9.3, 9.6, and 11.4 mIU/mg creatinine, P=0.01). We reexamined former smokers and number of cigarettes in the full model and found that current smokers had higher urinary FSH levels than both never-smokers (P=0.04) and former smokers (P=0.03). There was no significant difference between the never and former smokers (P=0.6). Urinary FSH did not differ by number of cigarettes smoked by current smokers (P=0.5).

## DISCUSSION

In this study we found that mother's age at menopause may help predict the daughter's urinary FSH value. A subject's smoking status and BMI were also important, with smoking associated with higher FSH and excess weight associated with lower FSH. These findings support the hypothesis that both genetic and environmental factors contribute to FSH level and presumably to ovarian aging for which FSH is a biomarker.

Previous studies have shown that a woman's age at menopause is related to her mother's age at menopause.<sup>11–13</sup> This relationship may be due to genetics or common behaviors, such as tobacco use, dietary intake, and physical activities. A genetic hypothesis is supported by

twin studies, which reveal a heritability for age at menopause of 63%.<sup>22</sup> Pedigree analyses have revealed a potential dominant pattern of inheritance of early menopause (menopause between ages 40 and 45) and premature ovarian failure (menopause prior to age 40) through maternal or paternal relatives.<sup>23,24</sup> One potential familial cause of early menopause and premature ovarian failure are alterations in the FMR1 gene. Mutation of the FMR1 gene, due to expansion of the CGG repeat to over 200 copies, leads to Fragile X syndrome. Trinucleotide repeats of 50–200 in the FMR1 gene is associated with premature ovarian failure.<sup>25</sup> The length of the trinucleotide repeat has been correlated with age at menopause.<sup>26</sup> Women with longer repeat sequences had earlier onset of menopause and women with shorter sequences had later onset.

Similarities in mother and daughter ages at menopause may also be attributed to common habits such as smoking, education level, and diet/exercise resulting in similar BMI.<sup>13</sup> However, when we controlled for these factors the effect of maternal age of menopause on FSH was not reduced, suggesting that the impact of maternal timing of menopause could be largely due to genetic phenomena rather than shared environment.

Environmental factors that predict age of menopause also appear to be associated with elevated FSH levels. Current smoking and unilateral oophorectomy both appear to result in earlier onset of menopause<sup>27–29</sup> and higher premenopausal FSH levels<sup>2,5,30,31</sup> while moderate alcohol use and increases in body mass index have been associated with delayed onset of<sup>11,12,32</sup> menopause. BMI has also been associated with lower premenopausal FSH levels.<sup>3,21</sup>

Although their mechanisms may differ, these factors may ultimately be linked to variation in the size or quality of the oocyte pool, presumably resulting in changes in serum FSH levels and in timing of onset of menopause.

Our findings that mother's age at menopause predicts daughter's FSH levels suggests that when FSH is used to monitor environmental impacts of potential reproductive toxicants on ovarian physiology, data on mother's age of menopause should be collected as a potential confounder or to improve precision of estimates. Future studies of younger women may determine whether the disparity in FSH between women with early and late maternal menopausal ages is due to a difference in the size of the initial oocyte pool or due to a difference in the rate of oocyte depletion.

In our study of women between 35 and 46 years of age, we did not detect a significant relationship between urinary FSH and age. This finding may be due to several factors. First, this could be a chance result of our selection criteria. Second, the age range in our analysis was narrow. Third, we focused on younger women than have usually been described in the literature. The association between age and FSH may not be as strong in this age range as in older ages. NHANES III survey showed that for the majority of women FSH remains relatively stable until age 45, when the values begin to rise.<sup>5</sup>

This study is limited by the fact that daughters provided the age at which their mothers went through menopause. The validity of this form of data collection has not been tested and has the potential for exposure misclassification due to preferential recall by the perimenopausal subjects. Also, many mothers underwent hysterectomy prior to natural menopause and before age 50. We were unable to include them in the analysis, thus limiting the power of our study, increasing the probability that chance may explain the study findings. In addition, not all women are able to provide information on their mother's age at menopause (only 62% in our sample).

Although, they did not have significant differences in mean urinary FSH values, women who are able to provide information about their mother's age at menopause do differ from those that do not. Postmenopausal women were not included in our study; however, we limited the analysis to women age 46 and younger, an age group from which very few women were excluded due to early natural menopause. The study is strengthened by the collection and assessment of multiple covariates. The study may have benefited from collection and adjustment for other conditions thought to impact on FSH such as ovarian surgery.

## CONCLUSIONS

Maternal age at menopause is a significant predictor of urinary FSH, a marker of ovarian aging. Urinary FSH is an important independent predictor of ovarian aging independent of age. FSH is influenced by genetic and environmental factors, such as tobacco use and body mass index. Epidemiologic studies using FSH as a marker of reproductive toxicity should consider collecting information on maternal age at menopause from study participants.

## Acknowledgments

This study was funded as intramural research at the NIH, National Institute of Environmental Health Sciences with support from the Office of Research on Minority Health and by the Women's Reproductive Health Research Career Development Center Grant 5K12 HD050113-02 at the University of North Carolina.

Freya Kamel, Ruby Nguyen, Nanette Santoro, Richard S. Legro, and Lauren A. Wise reviewed an earlier draft of the manuscript. This research was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences, the Office of Research on Minority Health, and the Women's Reproductive Health Research Career Development Center Grant 5K12 HD050113-02 at the University of North Carolina.

## References

1. Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW). *Fertil Steril* 2001;76(5):874–878. [PubMed: 11704104]
2. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. *Fertil Steril* 1989;51(4):651–654. [PubMed: 2494082]
3. Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. *J Clin Endocrinol Metab* 1995;80(12):3537-3545.
4. Lenton EA, Sexton L, Lee S, Cooke ID. Progressive changes in LH and FSH and LH: FSH ratio in women throughout reproductive life. *Maturitas* 1988;10(1):35–43. [PubMed: 3135465]
5. Backer LC, Rubin CS, Marcus M, Kieszak SM, Schober SE. Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35–60 in the U.S. population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988–1994). *Menopause* 1999;6(1):2935.
6. Oosterhuis GJ, Vermes I, Michgelsen HW, Schoemaker J, Lambalk CB. Follicle stimulating hormone measured in unextracted urine throughout the menstrual cycle correlates with age and ovarian reserve. *Hum Reprod* 2002;17(3):641–646. [PubMed: 11870116]
7. Santoro N, Rosenberg Brown J, Adel T, Skurnick JH. Characterization of reproductive hormonal dynamics in the perimenopause. *J Clin Endocrinol Metab* 1996;81:1495–1501. [PubMed: 8636357]
8. Thomford PJ, Jelovsek FR, Mattison DR. Effect of oocyte number and rate of atresia on the age of menopause. *Reprod Toxicol* 1987;1(1):41–51. [PubMed: 2980363]
9. Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. *Am J Epidemiol* 2001;153(9):865–874. [PubMed: 11323317]
10. Torgerson DJ, Thomas RE, Reid DM. Mothers and daughters menopausal ages: is there a link? *Eur J Obstet Gynecol Reprod Biol* 1997;74(1):63–66. [PubMed: 9243205]



11. Torgerson DJ, Thomas RE, Campbell MK, Reid DM. Alcohol consumption and age of maternal menopause are associated with menopause onset. *Maturitas* 1997;26(1):21–25. [PubMed: 9032743]
12. Torgerson DJ, Avenell A, Russell IT, Reid DM. Factors associated with onset of menopause in women aged 45–49. *Maturitas* 1994;19(2):83–92. [PubMed: 7968648]
13. Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. *Fertil Steril* 1995;64(4):740–745. [PubMed: 7672145]
14. Baird DD, Kesner JS, Dunson DB. Luteinizing hormone in premenopausal women may stimulate uterine leiomyomata development. *J Soc Gynecol Investig* 2006;13(2):130–135.
15. Kesner JS, Knecht EA, Krieg EF Jr. Stability of urinary female reproductive hormones stored under various conditions. *Reprod Toxicol* 1995;9(3):239–244. [PubMed: 7579908]
16. Hansen LM, Batzer FR, Gutmann JN, Corson SL, Kelly MP, Gocial B. Evaluating ovarian reserve: follicle stimulating hormone and oestradiol variability during cycle days 2–5. *Hum Reprod* 1996;11(3):486–9. [PubMed: 8671251]
17. Penarrubia J, Fabregues F, Manau D, Creus M, Casamitjana R, Carmona F, et al. Initial analysis of variability among basal hormone biomarkers of ovarian reserve. *Reprod Biomed Online* 2004;8(2):191–195. [PubMed: 14989797]
18. Kesner JS, Knecht EA, Krieg EF Jr. Time-resolved immunofluorometric assays for urinary luteinizing hormone and follicle stimulating hormone. *Analytica Chimica Acta* 1994;285:13–22.
19. Jaffe M. Ueber den neiderschlag, welchen pikrinsaeure im normalen harn erzeugt und ueber eine neue reaction des kreatinins. *Z Physiol Chem* 1986;13:491–400.
20. Kesner JS, Knecht EA, Krieg EF Jr, Wilcox AJ, O'Connor JF. Detecting pre-ovulatory luteinizing hormone surges in urine. *Hum Reprod* 1998;13(1):15–21. [PubMed: 9512221]
21. Santoro N, Lasley B, McConnell D, et al. Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: The Study of Women's Health across the Nation (SWAN) Daily Hormone Study. *J Clin Endocrinol Metab* 2004;89(6):2622–2631.
22. Snieder H, MacGregor AJ, Spector TD. Genes control the cessation of a woman's reproductive life: a twin study of hysterectomy and age at menopause. *J Clin Endocrinol Metab* 1998;83(6):1875–1880. [PubMed: 9626112]
23. Tibiletti MG, Testa G, Vegetti W, et al. The idiopathic forms of premature menopause and early menopause show the same genetic pattern. *Hum Reprod* 1999;14(11):2731–2734. [PubMed: 10548611]
24. Vegetti W, Marozzi A, Manfredini E, et al. Premature ovarian failure. *Mol Cell Endocrinol* 2000;161(1–2):53–57. [PubMed: 10773392]
25. Sherman SL. Premature ovarian failure in the fragile X syndrome. *Am J Med Genet* 2000;97(3):189–194. [PubMed: 11449487]
26. Ennis S, Ward D, Murray A. Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers. *Eur J Hum Genet* 2006;14(2):253–255. [PubMed: 16251893]
27. Hardy R, Kuh D. Reproductive characteristics and the age at inception of the perimenopause in a British National Cohort. *Am J Epidemiol* 1999;149(7):612–620. [PubMed: 10192308]
28. McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. *Ann Intern Med* 1985;103(3):350–356. [PubMed: 4026083]
29. Gold EB, Bromberger J, Crawford S, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. *Am J Epidemiol* 2001;153(9):865–874. [PubMed: 11323317]
30. Cramer DW, Barbieri RL, Fraer AR, Harlow BL. Determinants of early follicular phase gonadotrophin and estradiol concentrations in women of late reproductive age. *Hum Reprod* 2002;17(1):221–227. [PubMed: 11756392]
31. Cooper GS, Baird DD, Hulka BS, Weinberg CR, Savitz DA, Hughes CL Jr. Follicle-stimulating hormone concentrations in relation to active and passive smoking. *Obstet Gynecol* 1995;85(3):407–411. [PubMed: 7862381]
32. MacMahon B, Worcester J. Age at menopause. United States--1960–1962. *Vital Health Stat* 1966;11(19):1–20.





**Table 1**

Relationship between maternal age at menopause and daughter's urinary FSH

Maternal age at menopause	Number of Subjects (n=182)	Urinary FSH of Daughter, mIU/mg creatinine		
		Mean (SD)	Age-adjusted mean (95% CI) <sup>a</sup>	Fully-adjusted mean (95% CI) <sup>a,b</sup>
<46 y	25	13.4 (9.2)	11.0 (8.5–14.3)	11.7 (9.0–15.2)
46–49 y	23	12.5 (6.6)	10.8 (8.2–14.1)	10.9 (8.3–14.2)
≥50 y	134	10.5 (8.0)	8.5 (7.6–9.5)	8.4 (7.5–9.4)
P-value <sup>c</sup>		0.037	0.038	0.01

FSH, follicle stimulating hormone\* Linear regression test of trend.

<sup>a</sup> Analysis does not include subjects, whose a After back-transformation from log FSH.

<sup>b</sup> Adjusted for age, current smoking status (yes/no) and body mass index.

<sup>c</sup> Linear regression test of trend.